- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- FDA approves Plan B One-Step OTC switch
- FDA issues sweeping new requirements for long-acting opioids
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- FDA to recommend rescheduling of opioid painkiller hydrocodone from CIII to CII
PALATINE, Ill. — The Food and Drug Administration has accepted for review an application for a pain medication designed to thwart drug abusers.
Acura Pharmaceuticals announced Monday the acceptance of King Pharmaceuticals’ application for Acurox (oxycodone hydrochloride). King developed the drug using Acura’s Aversion technology, which is designed to limit or impede the ability to abuse the drug by dissolving or crushing the pills and then injecting them.
The FDA has granted the drug priority-review status and will take action on the application in June.